Novantrone Articles
Serono's 3rd-qtr 2006 sales rise 8.4% on Rebif
30 October 2006
Serono's net income up 8% in 2nd-qtr
31 July 2006
Stock Commentary - Europe
13 June 2005
Stock Commentary - Europe
6 June 2005
UPDATE: Serono tops forecasts as EPS rockets 54%
1 November 2004
Serono sees 3rd-qtr net income leaps 47%
1 November 2004
Serono's 2nd-qtr net income jumps 26%
2 August 2004
Serono's 1st-qtr income rockets 76.4%
26 April 2004
Serono
5 May 2003
OSI in $55M deal to sell Serono's Novantrone
17 March 2003
Serono sees 15%-20% growth for 2003
10 February 2003
Novuspharma's BBR 2778 shows promise as MS treatment
13 September 2001
Strong 2000 results for Immunex
26 January 2001
FDA approvable letter for Novantrone in MS
3 March 2000
Stock Commentary New York
3 February 2000
Immunex' Novantrone up for review
27 January 2000
Immunex Files sNDA For Novantrone In MS
3 June 1999
Novantrone: long-term benefits in secondary MS
29 April 1999
Stock Commentary New York
29 April 1999
Mitoxantrone Filing For MS In Second-Quarter '99?
8 December 1998
Novantrone Delays Disability In Progressive MS Patients
18 September 1998
Vertex' MDR Inhibitor Incel
29 July 1998
Cancer: New Therapeutics, And Quality Of Life
30 April 1998
US 3rd Quarter Results Show Strong Growth
22 October 1997
US Biopharma Firms See Research Bear Fruit In '96
17 February 1997
Immunex' Novatrone Approved In USA
25 November 1996
Novantrone Scheduled For Review Next Month
19 August 1996
FDA Approval For Immunex' Etoposide
25 March 1996
Phase III Results For Pixykine In Bone Marrow Transplant
6 November 1995
AHP Bid For Cyanamid Will Broaden Product Range
15 August 1994
CANCER MEDICINES IN DEVELOPMENT
14 June 1993
BREAST CANCER US RESEARCH UPDATE
26 April 1993
Showing 1-36 of 36 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
